Cancer
Recent research has presented a fresh understanding of melanomas, a type of skin cancer, using genetic engineering of T cells to target the ganglioside GD2, a tumor-associated antigen found in a high proportion of melanoma cells. The study, published in Clinical Cancer Research, reveals that genetically engineered T cells can
Cancer research
Recent research from Kaohsiung, Taiwan, has shed light on the additive effects of C(2)-ceramide on paclitaxel-induced premature senescence of human lung cancer cells. The study, published in Life Sciences, aimed to investigate the role of C(2)-ceramide in sensitizing cancer cells to paclitaxel treatment and to examine
Cancer
American Apparel, a clothing manufacturer and distributor, was sued by the US Equal Employment Opportunity Commission (EEOC) for terminating a disabled garment worker while he was on medical leave for cancer treatment. The EEOC argues that the company denied the worker's request for reasonable accommodation and fired him
Cancer research
Scientists are making significant strides in cancer therapy, moving away from broad-spectrum treatments towards targeted approaches that exploit the weaknesses of tumor cells. Researchers have discovered unique, highly specific drugs that inhibit DNA repair pathways, which are often dysregulated in cancer. These advancements in nanotechnology and drug discovery have led
Scientists
A recent report published in Biology of Blood and Marrow Transplantation presents fresh data on the cost-effectiveness of allogeneic peripheral blood stem cell transplantation (PBSCT) versus bone marrow transplantation (BMT) in pediatric patients with acute leukemia. Researchers from the United States conducted a retrospective study evaluating the cost and cost-effectiveness
Scientists
Scientists investigating the use of the histone deacetylase inhibitor, sodium butyrate (NaB), as a potential treatment for pancreatic cancer have made a significant discovery. The research, published in Current Therapeutic Research - Clinical and Experimental, found that NaB not only induces the expression of the tumor-suppressor gene p53 but also
Cancer
Researchers in the United Kingdom are developing trastuzumab emtansine, an antibody-drug conjugate, for the treatment of HER2+ metastatic breast cancer. Studies have shown that trastuzumab emtansine is effective in breast cancer cell lines resistant to trastuzumab and demonstrated complete tumor regression in SCID mice bearing KPL4 breast cancer xenografts. Clinical
Cancer
Researchers from Kyoto University, Japan, have made a groundbreaking discovery in the fight against metastatic lung cancer. By combining all-trans-retinoic acid (ATRA) with cationic liposome/interleukin 12 (IL-12) plasmid DNA (pDNA) complexes, they were able to enhance growth inhibition of metastatic lung tumors in mice. This innovative treatment approach showed
Cancer research
Probactive Biotech, Inc., a Garden Grove, California-based corporation, has joined forces with the Dalat Nuclear Research Institute in Vietnam to co-develop innovative cancer drugs. The collaboration leverages the strengths of both parties, combining Probactive's expertise in antitumor antibodies with the Dalat Institute's experience in producing medical-grade
Cancer research
MorphoSys, a leading biotechnology company, has been awarded a research grant by the German Federal Ministry of Education and Research to accelerate the development of its HuCAL-based cancer program MOR202 for the treatment of multiple myeloma. The funding of approximately EUR 1 million will support the Company in exploring relevant
Cancer treatment
Researchers at the University of California have developed a new formulation of doxorubicin, a chemotherapy drug commonly used to treat non-Hodgkin's lymphoma (NHL), by conjugating it with a monoclonal antibody that targets the CD22 protein. This new formulation, called CD22-targeted immunoliposomal doxorubicin (IL-PLD), has shown improved efficacy and
Cancer treatment
Research by scientists at Georgetown University's Lombardi Comprehensive Cancer Center has uncovered new findings in the relationship between estrogen receptors and breast cancer risk. A study using genetically engineered mouse models found that both increased expression of estrogen receptor alpha (ER(alpha)) and germline disruption of one p53
